CN113825755A - 作为irak4抑制剂的咪唑并吡啶类化合物 - Google Patents

作为irak4抑制剂的咪唑并吡啶类化合物 Download PDF

Info

Publication number
CN113825755A
CN113825755A CN202080036574.8A CN202080036574A CN113825755A CN 113825755 A CN113825755 A CN 113825755A CN 202080036574 A CN202080036574 A CN 202080036574A CN 113825755 A CN113825755 A CN 113825755A
Authority
CN
China
Prior art keywords
compound
isomer
group
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080036574.8A
Other languages
English (en)
Other versions
CN113825755B (zh
Inventor
王建非
李婕
谭海忠
张杨
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN113825755A publication Critical patent/CN113825755A/zh
Application granted granted Critical
Publication of CN113825755B publication Critical patent/CN113825755B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类IRAK4抑制剂，及其在制备治疗与IRAK4相关疾病的药物中的应用。具体涉及式(II)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080036574.8A 2019-06-26 2020-06-24 作为irak4抑制剂的咪唑并吡啶类化合物 Active CN113825755B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2019105621646 2019-06-26
CN201910562164 2019-06-26
CN2019106196047 2019-07-10
CN201910619604 2019-07-10
CN2019112408512 2019-12-06
CN201911240851 2019-12-06
CN2020104660059 2020-05-28
CN202010466005 2020-05-28
PCT/CN2020/098259 WO2020259626A1 (zh) 2019-06-26 2020-06-24 作为irak4抑制剂的咪唑并吡啶类化合物

Publications (2)

Publication Number Publication Date
CN113825755A true CN113825755A (zh) 2021-12-21
CN113825755B CN113825755B (zh) 2023-04-25

Family

ID=74061518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080036574.8A Active CN113825755B (zh) 2019-06-26 2020-06-24 作为irak4抑制剂的咪唑并吡啶类化合物

Country Status (3)

Country Link
US (1) US20220227758A1 (zh)
CN (1) CN113825755B (zh)
WO (1) WO2020259626A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4366834A1 (en) * 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途
WO2024020522A1 (en) * 2022-07-22 2024-01-25 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
WO2017108744A1 (de) * 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN107406416A (zh) * 2014-11-26 2017-11-28 拜耳医药股份有限公司 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN108026065A (zh) * 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911652A1 (en) * 2019-01-18 2021-11-24 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN107406416A (zh) * 2014-11-26 2017-11-28 拜耳医药股份有限公司 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN108026065A (zh) * 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
WO2017108744A1 (de) * 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途

Also Published As

Publication number Publication date
CN113825755B (zh) 2023-04-25
US20220227758A1 (en) 2022-07-21
WO2020259626A1 (zh) 2020-12-30

Similar Documents

Publication Publication Date Title
CN105189456B (zh) Kras g12c的共价抑制剂
CN113825755A (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
HUE031955T2 (en) New pyrrole pyrimidine compounds as inhibitors of protein kinases
JP7088906B2 (ja) Ｆｇｆｒ４阻害剤並びにその製造方法及び使用
CN109010343A (zh) 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途
CN112654619A (zh) 三环并呋喃取代哌啶二酮类化合物
CN116848112A (zh) 吡啶[4，3-d]嘧啶类化合物
CN113321654B (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
CA3114646C (en) Quinolino-pyrrolidin-2-one derivatives and application thereof
JP2022542162A (ja) ヘテロ環式アミド化合物及びその製造方法並びに使用
JP2023548204A (ja) Ｃｄ７３阻害剤及びその応用
WO2019137201A1 (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
JP2023503482A (ja) Ｊａｋ阻害剤としての三複素環式化合物及びその使用
CN114761411A (zh) 作为erk抑制剂的螺环类化合物及其应用
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
CN114008046B (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN115667258A (zh) 氟代吡咯并吡啶类化合物及其应用
WO2021159372A1 (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
CN114728966A (zh) 作为mnk抑制剂的吡咯并三嗪类化合物
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
CN114072401B (zh) 作为irak4和btk多靶点抑制剂的噁唑类化合物
CN116783178A (zh) 含联环的tyk2抑制剂化合物
CN111971285A (zh) 咪唑并吡咯酮化合物及其应用
CN115003672A (zh) 喹啉并咪唑类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant